Patient-Reported Outcomes among Multiple Myeloma Patients Treated with Standard of Care Idecabtagene Vicleucel

Patient-Reported Outcomes among Multiple Myeloma Patients Treated with Standard of Care Idecabtagene Vicleucel

Idecabtagene vicleucel (ide-cel) was the first FDA-approved chimeric antigen receptor T-cell therapy for relapsed/refractory multiple myeloma (RRMM) patients. This was the first study to evaluate patient-reported outcomes (PROs) among RRMM patients receiving ide-cel in standard of care (SOC). We pro...

Full description

Bibliographic Details
Main Authors: Laura B. Oswald, Lisa M. Gudenkauf, Xiaoyin Li, Gabriel De Avila, Lauren C. Peres, Kedar Kirtane, Brian D. Gonzalez, Aasha I. Hoogland, Oanh Nguyen, Yvelise Rodriguez, Rachid C. Baz, Kenneth H. Shain, Melissa Alsina, Frederick L. Locke, Ciara Freeman, Omar Castaneda Puglianini, Taiga Nishihori, Hien Liu, Brandon Blue, Ariel Grajales-Cruz, Heather S. L. Jim, Doris K. Hansen
Format: Article
Language:English
Published: MDPI AG 2023-09-01
Series:Cancers
Subjects:
quality of life
patient-reported outcomes
multiple myeloma
CAR T-cell therapy
Online Access:https://www.mdpi.com/2072-6694/15/19/4711

Internet

https://www.mdpi.com/2072-6694/15/19/4711

Similar Items